Invest in Global Kinetics private stocks

PREVIOUS ROUNDS

$1,280,443

invested through OurCrowd in

3 previous rounds.

Access exclusive deals

Join for free and be notified of future investment opportunities

WEBSITE

pkgcare.com.au

Healthcare

Overview: Global Kinetics

Global Kinetics’ primary technology platform is the Personal KinetiGraph (PKG®), a wearable biosensor device that automatically records patient mechanics to assist medical practitioners diagnose and treat patients with physical movement disorders, in particular, those with Parkinson’s disease. Worn as an unobtrusive wristwatch device, the commercial-stage PKG provides continuous and objective measurement of a patient’s symptoms in everyday environments. The platform’s proprietary algorithms record body movements and other symptoms over the course of several days, generating data-driven reports for practitioners to learn more detailed information. With better information, including reaction to medication, physical changes, or other issues, medical professionals create or change personalized treatment protocols, bringing patients a higher quality of life and helping lower health care costs. During the Covid-19 pandemic, PKG’s capabilities to remotely monitor patients from home or in non-clinical telehealth situations were instrumental in enabling continued treatment and diagnoses, and assisted healthcare providers receive reimbursements for remote protocols that have become more ubiquitous with the pandemic. Global Kinetics’ device has generated more than 7 million hours of clinical data with more than 30,000 Parkinson’s disease patients around the world. The PKG wearable system is both FDA 510(k) cleared in the US and CE-marked for the EU.

The details here are based on information received from, and verified solely by, the company.

Co Investors

Brandon Capital Partners

Global Kinetics Management Team

Timothy Still

President & CEO

Timothy Still is an accomplished CEO with 26 years’ experience in diagnostics technology companies such Xagenic and Accumetrics. Mr. Still has started working with GKC teams around the world to prioritize business development opportunities, align the organization and resources, and plan for the future fundraising necessary to help GKC realize its goals.

Prof. Malcolm Horne

Chief Scientist

Malcolm is a recognised leader in PD clinical practice and research. Prof. Horne leads the Neurodegeneration Division of the Florey Institute of Neuroscience and Mental Health, he is Professor of Neuroscience at University of Melbourne and manages a clinical practice in movement disorders at St Vincent’s Hospital, Melbourne.

Stefan Asberg

European Sales

Stefan has extensive experience within the Pharma industry as Global Marketing Manager for the Parkinson’s disease advanced therapy Duodopa (owned by AbbVie) and with pharmaceuticals and devices/ diagnostic tests at Pharmacia, leading new product launches and building and managing marketing teams. He has had extensive involvement in marketing and market access. Stefan also has experience in building long lasting relations with KOLs and key customers and working closely with medical teams to introduce new treatments and medical tests.

Pratyush Misra

Asia Pacific Sales

Praytush has previous experience working as a product manager within the pharmaceuticals industry. Most recently, Praytush was a Product Manager with Hospira with primary product responsibility for Apomine for the treatment of Parkinson’s Disease. Along with his product management experience, Praytush has experience in developing and managing relationships with KOLs and key customers.

undefined undefined